Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Perhaps her experience is a positive, in that they couldn't find any professional remotely connected with respiratory issues to say anything negative about SNG and thus balance the article?
Both (cross ramp removed) and Avacta are working on developing so-called 'lateral flow' tests for Covid-19, which give results in minutes. While other lateral flow tests have already reached the market, they are plagued by low reliability. As such, the successful development of a reliable alternative could still be rocket fuel for either stock, given the improvement in testing regimes that that would imply.
Totally agree, here’s hoping this is the beginning of an exciting next stage.
I’m expecting to see a decent double digit percentage rise off the back of this tomorrow :-)
Always love your posts, thank you for keeping a smile on our faces.
Here's hoping your police fine can be comfortably covered by your imminent AVCT profits ;-)!!
I would imagine that if it is government delays (which I think it is) he can't come out and say as much as doesn't want to **** off the Govt as they will likely be our main first customer, so although frustrating he has to just stay quiet.
I’m also holding all my 150k shares till JV or takeover, one of which will happen this year, and I’d expect to get north of £20.
It’s been a rollercoaster over the last 9 months for me in this share, and looking back I really wish I had traded to increase my holding, but I know I don’t have the ability or nerve to have done it!
Happy New Year to everyone and thank you to all the great posters on this board who have helped along the way, your time and knowledge is really appreciated.
Here’s to a prosperous and healthy 2021 for all of us.
SNG covered from 3:13 to 13:30 mins.
Worth a listen for newer or potential investors as it covers the journey during 2021. Nothing new for well researched investors.
Key comment was “the SNG board reads like a who’s who of the biotech and pharmaceutical world”.
@Parsley2, thanks, I was focussing on the TAM, assuming high rates of vaccine take up and efficacy (and we know those percentages are open to debate).
The Total Addressable Market is still huge, but you are right we would need the right people (governments) to be on board, but it’s my firm belief that if all we did was produce 1.2m treatments during 2021, we would sell them all. Even if we never increased or sold any more, which of course wouldn’t happen. At the price RM has said, we would have a profit far higher than our current MCAP.
The unnerving times we are in now represent a similar buying opportunity that some of us saw pre Manic Monday when Acacia were selling down and we were bumping around 35p for weeks.
If we take the adult populations of Canada, USA, U.K. & the EU, we have roughly 707m people, made up as follows.
Canada - 25m
U.S.A. - 250m
U.K. - 47m
Europe - 385m
=======
707m
Let’s say the vaccine is taken by 80% of the population,
707m x 80% = 565.6m take the vaccine
and then say it is actually 90% effective,
565.6 x 90% effectiveness = 509.4m ‘sorted’.
That means that:
707m - 509.4m
Just under 200m adults in the Western world are potential patients for SNG0001. (This is ignores all COPD potential).
Plus... 652m total people live in Latin America,
and a further 1.35 billion live in India.
Do you know what, I think we will be ok even if we increase product to 1 million doses a month for the next few years..
I recall it said c.20 so circa, or about/approximately, so I don’t see 26 as a deviation of the c.20.
YoYoY
Thanks for asking ...The top 16 FTSE 100 companies all have Mcaps in excess of £30bn.
However if you read my post as me saying that RMS would get to £30bn MCAP then you’ve mis-read me, I was merely checking a poster had meant to put this could get to £20per share, which would be a MCAP of £30bn.
To me, even in the medium term that seems a stretch to say the least!
£30bn MCAP?
Comparison of seven commercial SARS-CoV-2 rapid Point-of-Care Antigen tests:
https://twitter.com/michaelmina_lab/status/1327720372318441473?s=21
Still here in full, wasn’t fun seeing paper value drop, but my timeline was always well into 2021, and a ‘vaccine’ appearing was never not going to happen - so whilst it felt bad, I’m remaining fully in and positive!
Surely Avacta would be at least a DVD in comparison to NCYT/Betamax?!
Thanks both.
Could it be us?
£200 ex-Chin-ah
Are you able to share any more please?
The company is building itself into an excellent position and one which it can negotiate from strongly.
Assuming P3 confirms that we know already, works for CoVID and is safe and can be used with steroids.
Plus we are already on track for £1.2bn revenues for 2021, I can’t see why our MCap would get to a minimum, minimum of £5bn (=£25 per share), and frankly if we get bought out in a bidding war, the. £10bn MCap is easily attainable.
National lockdown rumours - as early as Wednesday..
https://www.google.co.uk/amp/s/www.independent.co.uk/news/uk/politics/coronavirus-second-wave-lockdown-boris-johnson-sage-b1459842.html%3famp
Isn’t he still in PL75’s basement?!